PharmaVoice 29. Jan. 2026 Eli Lilly, BioAge chase NLRP3 inhibitors with ‘pipeline in a pill’ potential
PharmaVoice 27. Jan. 2026 A potential gene therapy for heart failure is an approach decades in the making
PharmaVoice 20. Jan. 2026 Texas, N. Carolina, Ohio, Pennsylvania — where pharma manufacturing investments have surged
PharmaVoice 15. Jan. 2026 It’s crunch time for US biopharma M&A. Can drugmakers strike deals despite persisting anxieties?
PharmaVoice 14. Jan. 2026 Lilly, Novo test direct-to-employer approach that could cut out PBMs and lower costs